VISTA: A promising target for overcoming immune evasion in gynecologic cancers
International Immunopharmacology · 2024-09 · 138 · 112655
DOI: 10.1016/j.intimp.2024.112655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Sicong Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, B7 Antigens, Tumor Microenvironment, Tumor Escape. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell activation), a member of the B7 family, is emerging as another checkpoint that regulates the anti-tumor immune responses within the tumor microenvironment. This paper reviews the structure, expression, and mechanism of action of VISTA. Furthermore, it highlights recent advances in VISTA-blocking therapies and their potential in improving outcomes for patients with gynecologic cancers. By understanding the role of VISTA in mediating the immune evasion of gynecologic tumors, we can develop more effective combinatory treatment strategies that could overcome resistance to current ICB therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China.
- Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
- Department of Immunobiology, Yale University, New Haven, CT 06511, USA.
- Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. Electronic address: haolin@seu.edu.cn.
- Department of Immunobiology, Yale University, New Haven, CT 06511, USA. Electronic address: tianxiang.zhang@yale.edu.
- Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China. Electronic address: shenyang@seu.edu.cn.
Zitieren
APA
Liu, S., Ji, F., Ding, Y., Ding, B., Feng, S., Brennick, C., Lin, H., Zhang, T., & Shen, Y. (2024). VISTA: A promising target for overcoming immune evasion in gynecologic cancers. International Immunopharmacology, 138, 112655. https://doi.org/10.1016/j.intimp.2024.112655
Vancouver
Liu S, Ji F, Ding Y, Ding B, Feng S, Brennick C, et al. VISTA: A promising target for overcoming immune evasion in gynecologic cancers. International Immunopharmacology. 2024;138:112655. doi:10.1016/j.intimp.2024.112655
BibTeX
@article{Liu2024,
author = {Liu, Sicong and Ji, Feng and Ding, Yue and Ding, Bo and Feng, Songwei and Brennick, Cory and Lin, Hao and Zhang, Tianxiang and Shen, Yang},
title = {VISTA: A promising target for overcoming immune evasion in gynecologic cancers},
journal = {International Immunopharmacology},
year = {2024},
volume = {138},
pages = {112655},
doi = {10.1016/j.intimp.2024.112655}
}
EUVIMED